Cart
sales@molnova.com
SNDX-5613
CAS No. 2169919-21-3
SNDX-5613( —— )
Catalog No. M23982 CAS No. 2169919-21-3
SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 88 | In Stock |
|
| 5MG | 147 | In Stock |
|
| 10MG | 259 | In Stock |
|
| 25MG | 514 | In Stock |
|
| 50MG | 737 | In Stock |
|
| 100MG | 1017 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSNDX-5613
-
NoteResearch use only, not for human use.
-
Brief DescriptionSNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM).
-
DescriptionSNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias. (In Vivo):Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.
-
In Vitro——
-
In VivoRevumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
RecptorMenin-MLL
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2169919-21-3
-
Formula Weight630.82
-
Molecular FormulaC32H47FN6O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO:41.67 mg/mL (66.06 mM; Need ultrasonic)
-
SMILESO=C(C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(C3)CCN(CC4)C[C@H]5CC[C@@H](CC5)NS(=O)(CC)=O)N(C(C)C)CC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).
molnova catalog
related products
-
JIB-04
JIB-04 is a pan-selective Jumonji histone demethylase inhibitor.
-
M?89
M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemia.?M-89 is a highly potent and specific menin inhibitor, with a Kd of 1.4 nM for binding to menin.
-
MRTX-1719
MRTX-1719 is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC 50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells.
